Survivin基因修饰DCs疫苗激发抗喉癌作用的实验研究  

Experiment study of the anti-laryngeal cancer effects of dendritic cell-based survivin vaccine

作　　者：李红[1] 李明红[1] 彭莉[1] 杨桦[1] 镡旭民[1] 

机构地区：[1]第三军医大学附属新桥医院耳鼻咽喉头颈外科

出　　处：《免疫学杂志》2009年第5期510-514,共5页Immunological Journal

基　　金：国家自然科学基金资助(30672299)

摘　　要：目的构建survivin基因修饰DCs疫苗,并观察其生物学特性及其对喉癌治疗作用。方法通过同源重组构建人全长survivin-腺病毒载体(pAd-survivin),并转染未成熟DCs,诱导培养获取成熟DCs,激活T淋巴细胞的增殖;观察DCs疫苗在体内外的生物学活性。结果重组pAd-sur修饰DCs疫苗能显著刺激T淋巴细胞增殖;pAd-sur-DCs能促进T淋巴细胞IFN-γ分泌增加,与对照组比较差异具有显著意义;疫苗对体外细胞杀伤率51.46%,与对照组比较,差异具有显著意义;对移植瘤细胞凋亡率为54.9%,坏死率为21.87%,与对照组比较,差异具有显著意义。结论经survivin基因修饰后,DCs表面分子的表达率较未经基因修饰DCs显著增高,具备更强的刺激T淋巴细胞增殖,促进IFN-γ分泌;在体内外具有促进杀伤喉癌细胞的能力。Objective To construct human full-length survivin gene-modified DCs vaccine and observe its biological charact-eristics and the role in laryngeal cancer treatment.Methods Full-length survivin-human adenovirus(pAd-survivin)was constructed with homologous recombination,and transfected into immature DCs;the DCs were cultured and induced for obtaining mature DCs;the proliferation of T lymphocytes was activated.Biological activity of the DCs vaccine in different groups was observed in vitro and in vivo.Results D...

关 键 词：SURVIVIN 重组腺病毒载体 树突状细胞疫苗 喉癌 

分 类 号：R739.65[医药卫生—肿瘤]